Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FT596 in R/R B-cell Lymphoma and CLL
NCT04245722Phase 1Terminated
- Sponsor
- Fate Therapeutics
- Start
- Mar 2020
- Primary completion
- Sep 2023
- Modality
- Gene Editing, Gene Silencing, Patient-derived iPSCs
- Countries
- 1
01
Overview
Phase 1, open-label trial of FT596 in B cell lymphoma and chronic lymphocytic leukemia (CLL) (5 arms), sponsored by Fate Therapeutics. Primary endpoints: Incidence of dose-limiting toxicities within each dose level cohort at Day 29, Nature of dose-limiting toxicities within each dose level cohort at Day 29 and 1 more. Started Mar 2020; status: terminated.
02
Drugs
FT596
03
Conditions
B cell lymphomachronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT04245722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04245722.